Nektar Therapeutics Cash Flow Reinvestment Rate
Nektar Therapeutics cash flow reinvestment rate. Nektar Therapeutics (NKTR) has a Cash Flow Reinvestment Rate of 0.93x as of June 2018, reinvesting $897.05 Million (capex $2.75 Million plus investments $-894.30 Million) from operating cash flow of $959.64 Million. Explore NKTR operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Nektar Therapeutics (1997–2018)
Cash flow reinvestment rate of Nektar Therapeutics from 1997 to 2018. Historical reinvestment intensity for Nektar Therapeutics across 4 annual periods. Explore NKTR capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Nektar Therapeutics Cash Flow Reinvestment Rate by Year (1997–2018)
Nektar Therapeutics cash flow reinvestment rate by year from 1997 to 2018. Year-by-year capital reinvestment analysis for Nektar Therapeutics. For the full cash flow conversion analysis, see Nektar Therapeutics operating cash flow efficiency.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 1.93x | $1.38 Billion | $718.21 Million | $14.24 Million | ▲ +269.5% |
| 2009 | 0.52x | $20.70 Million | $39.74 Million | $20.70 Million | ▲ +132.4% |
| 2007 | 0.22x | $32.80 Million | $146.30 Million | $32.80 Million | ▼ -93.5% |
| 1997 | 3.47x | $17.26 Million | $4.98 Million | $17.26 Million | — |